Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuma Kishida

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Asia-Pacific Journal of Clinical Oncology|September 8, 2025
Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With PembrolizumabTakashi Matsuki, Takuro Okada, Chihiro Fushimi, et al.
Anticancer Research|February 27, 2022
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell CarcinomaTakuro Okada, Chihiro Fushimi, Takashi Matsuki, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Asia-Pacific Journal of Clinical Oncology|September 8, 2025
Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With PembrolizumabTakashi Matsuki, Takuro Okada, Chihiro Fushimi, et al.
Anticancer Research|February 27, 2022
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell CarcinomaTakuro Okada, Chihiro Fushimi, Takashi Matsuki, et al.
Pageof 3